Search Results - "Witztum, Joseph"

Statin therapy increases lipoprotein(a) levels by Tsimikas, Sotirios, Gordts, Philip L S M, Nora, Chelsea, Yeang, Calvin, Witztum, Joseph L

“…Abstract Aims Lipoprotein(a) [Lp(a)] is elevated in 20–30% of people. This study aimed to assess the effect of statins on Lp(a) levels. Methods and results…”
Get full text

History of Discovery: Oxidized Low-Density Lipoprotein and Atherosclerosis by Steinberg, Daniel, Witztum, Joseph L

Get full text

Innate sensing of oxidation-specific epitopes in health and disease by Binder, Christoph J., Papac-Milicevic, Nikolina, Witztum, Joseph L.

“…Key Points Oxidative stress results in the oxidative damage of membrane lipids, leading to the formation of neo-self epitopes, which are known as…”
Get full text

Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements by Yeang, Calvin, Witztum, Joseph L., Tsimikas, Sotirios

“…Current methods for determining “LDL-C” in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. We developed a…”
Get full text

'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering by Yeang, Calvin, Witztum, Joseph L, Tsimikas, Sotirios

“…The measurement that is termed 'LDL-cholesterol' (LDL-C) includes the cholesterol content of lipoprotein(a) [Lp(a)-C], which can contribute approximately…”
Get full text

Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol by Yeang, Calvin, Karwatowska-Prokopczuk, Ewa, Su, Fei, Dinh, Brian, Xia, Shuting, Witztum, Joseph L., Tsimikas, Sotirios

“…Laboratory methods that report low-density lipoprotein cholesterol (LDL-C) include both LDL-C and lipoprotein(a) cholesterol [Lp(a)-C] content. The purpose of…”
Get full text

Oxidized phospholipids in cardiovascular disease by Tsimikas, Sotirios, Witztum, Joseph L.

“…Prolonged or excessive exposure to oxidized phospholipids (OxPLs) generates chronic inflammation. OxPLs are present in atherosclerotic lesions and can be…”
Get full text

The influence of innate and adaptive immune responses on atherosclerosis by Witztum, Joseph L, Lichtman, Andrew H

“…Both the chronic development of atherosclerotic lesions and the acute changes in lesion phenotype that lead to clinical cardiovascular events are significantly…”
Get full text

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis by Zhao, Peng, Sun, Xiaoli, Chaggan, Cynthia, Liao, Zhongji, In Wong, Kai, He, Feng, Singh, Seema, Loomba, Rohit, Karin, Michael, Witztum, Joseph L, Saltiel, Alan R

“…Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of the energy sensor adenosine monophosphate (AMP)-activated…”
Get full text

RNA-Targeted Therapeutics by Crooke, Stanley T., Witztum, Joseph L., Bennett, C. Frank, Baker, Brenda F.

“…RNA-targeted therapies represent a platform for drug discovery involving chemically modified oligonucleotides, a wide range of cellular RNAs, and a novel…”
Get full text

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome by Witztum, Joseph L, Gaudet, Daniel, Freedman, Steven D, Alexander, Veronica J, Digenio, Andres, Williams, Karren R, Yang, Qingqing, Hughes, Steven G, Geary, Richard S, Arca, Marcello, Stroes, Erik S.G, Bergeron, Jean, Soran, Handrean, Civeira, Fernando, Hemphill, Linda, Tsimikas, Sotirios, Blom, Dirk J, O’Dea, Louis, Bruckert, Eric

“…This phase 3 trial showed that treatment with volanesorsen, an antisense oligonucleotide drug complementary to mRNA encoding apolipoprotein C-III, resulted in…”
Get full text

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels by Alexander, Veronica J, Xia, Shuting, Hurh, Eunju, Hughes, Steven G, O’Dea, Louis, Geary, Richard S, Witztum, Joseph L, Tsimikas, Sotirios

“…Abstract Aims Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an…”
Get full text

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials by Viney, Nicholas J, BSc, van Capelleveen, Julian C, MD, Geary, Richard S, PhD, Xia, Shuting, MS, Tami, Joseph A, PharmD, Yu, Rosie Z, PhD, Marcovina, Santica M, Prof, Hughes, Steven G, MD, Graham, Mark J, MS, Crooke, Rosanne M, PhD, Crooke, Stanley T, MD, Witztum, Joseph L, Prof, Stroes, Erik S, Prof, Tsimikas, Sotirios, Prof

“…Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific…”
Get full text

Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis by Willeit, Peter, Raschenberger, Julia, Heydon, Emma E, Tsimikas, Sotirios, Haun, Margot, Mayr, Agnes, Weger, Siegfried, Witztum, Joseph L, Butterworth, Adam S, Willeit, Johann, Kronenberg, Florian, Kiechl, Stefan

“…Short telomeres have been linked to various age-related diseases. We aimed to assess the association of telomere length with incident type 2 diabetes mellitus…”
Get full text

B Cells and Humoral Immunity in Atherosclerosis by Tsiantoulas, Dimitrios, Diehl, Cody J, Witztum, Joseph L, Binder, Christoph J

“…Insights into the important contribution of inflammation and immune functions in the development and progression of atherosclerosis have greatly improved our…”
Get full text

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study by Tsimikas, Sotirios, Prof, Viney, Nicholas J, BSc, Hughes, Steven G, MBBS, Singleton, Walter, MD, Graham, Mark J, MS, Baker, Brenda F, PhD, Burkey, Jennifer L, PhD, Yang, Qingqing, MS, Marcovina, Santica M, Prof, Geary, Richard S, PhD, Crooke, Rosanne M, PhD, Witztum, Joseph L, Prof

“…Summary Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower…”
Get full text

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis by Tsimikas, Sotirios, Fazio, Sergio, Ferdinand, Keith C., Ginsberg, Henry N., Koschinsky, Marlys L., Marcovina, Santica M., Moriarty, Patrick M., Rader, Daniel J., Remaley, Alan T., Reyes-Soffer, Gissette, Santos, Raul D., Thanassoulis, George, Witztum, Joseph L., Danthi, Simhan, Olive, Michelle, Liu, Lijuan

“…Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease…”
Get full text

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis by Capoulade, Romain, PhD, Chan, Kwan L., MD, Yeang, Calvin, MD, PhD, Mathieu, Patrick, MD, Bossé, Yohan, PhD, Dumesnil, Jean G., MD, Tam, James W., MD, Teo, Koon K., MBBCh, PhD, Mahmut, Ablajan, MD, MSc, Yang, Xiaohong, BSc, Witztum, Joseph L., MD, Arsenault, Benoit J., PhD, Després, Jean-Pierre, PhD, Pibarot, Philippe, DVM, PhD, Tsimikas, Sotirios, MD

“…Abstract Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification…”
Get full text

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III by Pechlaner, Raimund, MD, PhD, Tsimikas, Sotirios, MD, Yin, Xiaoke, PhD, Willeit, Peter, MD, PhD, Baig, Ferheen, MSc, Santer, Peter, MD, Oberhollenzer, Friedrich, MD, Egger, Georg, MD, Witztum, Joseph L., MD, Alexander, Veronica J., PhD, Willeit, Johann, MD, Kiechl, Stefan, MD, Mayr, Manuel, MD, PhD

“…Abstract Background Routine apolipoprotein (apo) measurements for cardiovascular disease (CVD) are restricted to apoA-I and apoB. Here, the authors measured an…”
Get full text

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice by Que, Xuchu, Hung, Ming-Yow, Yeang, Calvin, Gonen, Ayelet, Prohaska, Thomas A., Sun, Xiaoli, Diehl, Cody, Määttä, Antti, Gaddis, Dalia E., Bowden, Karen, Pattison, Jennifer, MacDonald, Jeffrey G., Ylä-Herttuala, Seppo, Mellon, Pamela L., Hedrick, Catherine C., Ley, Klaus, Miller, Yury I., Glass, Christopher K., Peterson, Kirk L., Binder, Christoph J., Tsimikas, Sotirios, Witztum, Joseph L.

“…Oxidized phospholipids (OxPL) are ubiquitous, are formed in many inflammatory tissues, including atherosclerotic lesions, and frequently mediate…”
Get full text